ArticleJournal of clinical medicine2021

JAK Inhibition with Ruxolitinib in Patients with COVID-19 and Severe Pneumonia: Multicenter Clinical Experience from a Compassionate Use Program in Italy.

Alessandro Maria Vannucchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.